Stocktoria
Enliven Therapeutics, Inc. ELVN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-03-12
Enliven Therapeutics, Inc. statistics & valuation
Market cap$3.6B
P / B7.8×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Return on assets | -21.8% | -27.3% | -26.3% | -45.2% | -54.9% |
| Return on equity | -22.6% | -28.7% | -29.1% | 49.0% | 119.8% |
| Current ratio | 28.66 | 19.99 | 10.28 | 8.00 | 12.86 |
Source: SEC EDGAR filings · CIK 0001672619 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.